Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 2Suspended 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 16Gastrointestinal 10Gynecologic 4Tumor-Agnostic 3CNS 3Thoracic 2Sarcoma 2Head & Neck 2Genitourinary 1

Conditions

Neoplasm Metastasis 3

Interventions

Specimen Handling 17Biopsy 16Magnetic Resonance Spectroscopy 10pembrolizumab 9Paclitaxel 6atezolizumab 5Standard of Care 5Bevacizumab 5trastuzumab deruxtecan 3ipatasertib 3durvalumab 3X-Rays 3Taxes 3Radiotherapy 3Exercise 3Cetuximab 3Carboplatin 3Capecitabine 3nilotinib 2inavolisib 2dostarlimab 2cabozantinib 2Tiragolumab 2Radiosurgery 2Radiation 2Practice Guidelines as Topic 2Pemetrexed 2Oxaliplatin 2Nivolumab 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
trastuzumab deruxtecan × Tumor-Agnostic × 30 days × Clear all
NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04585958 2026-05-20

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
55 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

National Cancer Institute (NCI)

Phase 1 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡